Close Menu

NEW YORK, June 11 – Canada’s Virtek Vision International said Monday that its Virtek ChipWriter and Virtek ChipReader had been selected for a six-month trial to apply its microarray technology for a neonatal screening application.

Under the terms of the alliance, Virtek has agreed to supply its spotter and reader to Neo Gen Screening and TeleChem International/ArrayIt.com for the testing of metabolic disorders in newborns. TeleChem of Sunnyvale, Calif., has developed the assays while Neo Gen Screening of Pittsburgh, Pa., develops tests for screening disorders.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.